Various Forms of Chemically Induced Liver Injury and Their Detection by Diagnostic Procedures*

by H. J. Zimmerman†

A large number of chemical agents, administered for therapeutic or diagnostic purposes, can produce various types of hepatic injury by several mechanisms. Some agents are intrinsically hepatotoxic, and others produce hepatic injury only in the rare, uniquely susceptible individual. Idiosyncrasy of the host is the mechanism for most types of drug-induced hepatic injury. It may reflect allergy to the drug or a metabolic aberration of the host permitting the accumulation of hepatotoxic metabolites. The syndromes of hepatic disease produced by drugs have been classified as hepatocellular, hepatocanalicular, mixed and canalicular. Measurement of serum enzyme activities has provided a powerful tool for studies of hepatotoxicity. Their measurement requires awareness of relative specificity, knowledge of the mechanisms involved, and knowledge of the relationship between known hepatotoxic states and elevated enzyme activities.

Drug-induced liver disease accounts for only a small proportion (less than 5%) of instances of jaundice in general hospitals (1,2). As a cause of severe, acute, hepatic disease with hepatic failure, however, adverse reactions to therapeutic agents (for example, halothane or isoniazid) figure more prominently. Hepatic necrosis induced by drugs accounts for 25 to 30% of instances of fulminant hepatic failure (3). Hepatic damage caused by therapeutic agents is best reviewed in the context of the general aspects of hepatotoxicity (4). These include the character of the injury and the presumed mechanisms and circumstances of exposure to the respective agent.

Types of Drug-Induced Hepatic Disease

Chemical agents can produce several types of hepatic injury (Table 1). The injury may be cytotoxic, that is, characterized by necrosis or degeneration of the hepatic parenchyma, or cholestatic, that is, manifested by arrested bile flow and jaundice, but relatively little parenchymal injury. Some drugs characteristically produce injury that includes elements of both types and is referred to as mixed. The cytotoxic form includes necrosis (zonal, diffuse, and massive), steatosis, or combinations of necrosis and steatosis. Cholestatic injury may be bland, that is, manifested only by bile stasis, without significant inflammatory changes in the liver, as in that produced by the C-17 alkylated anabolic or contraceptive steroids; or it may be accompanied by impressive portal area aggregates of inflammatory cells, as in the cholestatic injury induced by erythromycin estolate or chlorpromazine.

The correlation between the morphological

* Portions of this text were previously published in the Israel Journal of Medical Sciences [10:386, 328 (1974)]. These are reproduced with permission of the Israel Journal of Medical Sciences.

† Veterans Administration Hospital, Washington, D.C.
type of hepatic injury and the clinical and biochemical abnormalities is quite consistent. Hepatic necrosis induced by drugs leads to a syndrome which resembles that of viral hepatitis with markedly elevated transaminase valves and relatively slight elevations of the alkaline phosphatase levels. Most important is the tendency for this syndrome to present itself as massive hepatic necrosis and liver failure.

The hepatic steatosis produced by tetracycline resembles the histological picture the fatty liver of pregnancy and leads to similar biochemical features and clinical manifestations. Jaundice is usually modest and the transaminase values are only moderately elevated, but the syndrome of hepatic failure with a fatal outcome can develop.

Cholestasis injury resembles extrahepatic obstructive jaundice in its manifestation. The clinical picture is dominated by jaundice and itching. The biochemical parameters include modest transaminase elevations and alkaline phosphatase activities that resemble those of obstructive jaundice. This is the picture in the cholestatic jaundice associated with portal inflammation (hepatoanacanicular jaundice). (4) Alkaline phosphatase activities are more modestly elevated in the bland cholestasis induced by C-17 alkylated steroids (canalicular jaundice) (4).

Some drugs produce a mixed pattern of hepatic injury that includes both cytotoxic and cholestatic features. Hepatoanacanicular jaundice with prominent parenchymal injury accompanying the predominantly cholestatic picture has been characterized as mixed-hepatoanacanicular jaundice. Hepatocellular injury in which a predominantly cytotoxic form of damage is accompanied by very high alkaline phosphatase values has been designated mixed-hepatocellular jaundice (4).

Precise description of the phenomenology of the forms of drug-induced injury may have several advantages. The type of injury has a clear bearing on the prognosis. The more prominent the hepatocellular injury, the more grave the syndrome, with hepatic failure and a fatal outcome possible (4). The more cholestatic the injury and the less prominent the parenchymal damage, the better the immediate prognosis. The mortality rate in hepatocellular jaundice ranges from 10 to 50%, while in drug-induced cholestatic jaundice it is less than 1%. Furthermore, the type of injury is related to the therapeutic category of drug. For example, the antidepressants tend to produce hepatocellular injury, the anticonvulsants lead to mixed-hepatocellular injury, the tranquilizers, to hepatocanalicular or mixed-hepatocanalicular injury and the anabolic and contraceptive steroids produce the canalicular type of injury (5).

Chronic hepatic disease can also result from drug-induced injury. Acute hepatocellular injury induced by cinchophen, iproniazid and repeated exposure to halothane has been reported to lead to cirrhosis of the macronodular type (5). Protracted administration of methotrexate appears to lead, in some patients, to cirrhosis of the macro or micronodular type (6). In some patients, the hepatic injury induced by oxyphenisatin shows features of chronic active hepatitis, including cirrhosis (7). Cholestasis injury induced by chlorpromazine, organic arsenicals, tolbutamide, methyltestosterone and contraceptive steroids has led to instances of a cirrhosis resembling the "primary biliary" type (5). The Budd-Chiari syndrome, with congestive cirrhosis, can result from thrombotic occlusion of the hepatic veins induced by contraceptive steroids or by the venoocclusive disease and centrolobular hepatic sclerosis secondary to urethane poisoning (5).

**Mechanisms of Injury**

The chemical agents that produce hepatic damage fall into two broad categories: those that have the intrinsic property of injuring the liver (intrinsic or predictable hepatotoxins) and those that damage the liver of uniquely susceptible hosts (idiosyncracy-dependent or unpredictable toxins) (Table 2). The first group is recognizable by the high incidence of toxicity in exposed individuals, dependence on dose and reproducibility of the injury in a variety of species. Agents which produce hepatic injury in a small proportion of exposed individuals, whose toxicity is not dose-dependent and which do not produce hepatic damage in experimental animals, are recognized to depend on host idiosyncrasy rather than on the intrinsic toxicity of the agent (4, 5, 8, 9). Intrinsic hepatotoxins appear to include at least two subcategories, direct and indirect (Table 2). Direct hepatotoxins are protoplasmic poisons capable of injuring many tissues, particularly the liver. The prototype, carbon tetrachloride (CCL4) disrupts all elements of the hepatocyte including the endoplasmic reticulum, mitochondria, lysosomes, and plasma membranes and, indeed, leads to almost immediate, destructive intracellular chaos. The membrane injury appears to result from peroxidative damage of the
Table 1. Types of drug-induced acute hepatic injury.

| Histological                  | Biochemical* | Clinical                        | Prototype drugs |
|-------------------------------|--------------|---------------------------------|-----------------|
|                               | GOT-GPT      | Alkaline phosphatase Cholesterol| Syndrome resembles | Mortality, % |
| Cytotoxic                     |              |                                |                 |              |
| Necrosis: zonal and diffuse   | Markedly     | Increased                       | Viral hepatitis (severe) | 10-50        |
|                               | increased    |                                |                 |              |
| Steatosis                     | Increased    | Increased                       | Fatty liver of pregnancy | High         |
|                               | Normal to    | decreased                       |                 |              |
| Cholestatic                   |              |                                |                 |              |
| Pericholangitis (present)     | Increased    | Markedly                        | Obstructive jaundice | <1           |
|                               | Markedly     | increased                       |                 |              |
|                               | increased    |                                |                 |              |
| (absent)                      | Increased    | Increased                       | Obstructive jaundice | <1           |
|                               | Normal to    | increased                       |                 |              |
| Mixed*                        |              |                                |                 |              |
| Features cytotoxic plus       | Increased to | Increased to                    | Atypical viral hepatitis |              |
| cholestatic                   | markedly     | markedly                       |                 |              |
|                               | increased    | increased                       | Obstructive jaundice |              |
|                               | Decreased to | increased                      |                 |              |

* GOT=glutamate oxaloacetate transaminase; GPT=glutamate pyruvate transaminase.
* In mixed types, mortality seems to depend on the degree of cytotoxic injury.

Table 2. Classifications and characteristics of hepatotoxic agents.

| Category                        | Incidence | Experimentally reproducible | Dose dependence | Latent period                        | Mechanism                        | Histological lesion | Prototype drugs |
|---------------------------------|-----------|----------------------------|-----------------|--------------------------------------|-----------------------------------|---------------------|-----------------|
| Intrinsic toxicity              |           |                            |                 |                                      | Membrane injury indiscriminate of cell | Necrosis (zonal) and/or steatosis | CCl, Chloform Tannic acid |
| Direct                          | High      | Yes                        | Yes             | Very short (minutes to hours)        | Steatosis or necrosis              |                     | Ethionine        |
|                                 |           |                            |                 |                                      | Interference with specific metabolic pathways |                     | Urethane, Mycotoxins |
| Indirect Cytotoxic              | High      | Yes                        | Yes             | Short (hours to days)                | Bile casts                        |                     | Tetracycline, Cancer chemotherapy agents |
| Cholestatic                     | High      | Yes*                       | Yes             | Short (days)                         | Interference with hepatic excretory pathways |                     | Icterogenin C-17 alkylated anabolic and contraceptive steroids |
| Host idiosyncrasy               | Low       | No                         | No              | Consistent, long (one to four weeks) | Drug allergy                      | Necrosis or cholestasis | Sulfonamides, Paraminosalicylic acid |
| Hypersensitivity                |           |                            |                 |                                      |                                   |                     | Halothane        |
| Metabolic abnormality           | Low       | No                         | No              | Variable, long (weeks to months)     | ? Accumulation of hepatotoxic metabolites | Necrosis or cholestasis | Iproniaizid Cinchophen Isoniazid |

* Experimental reproducibility difficult but possible.
lipid components, wrought mainly by a metabolite of the CCl_{4}.

Indirect hepatotoxins are antimetabolites or related compounds, which produce hepatic injury by the diversion or competitive inhibition of essential metabolites or by other forms of interference with specific metabolic or secretory processes of the hepatocyte. Indirect hepatotoxins cripple the hepatocyte selectively by interference with a specific pathway, while direct toxins appear to produce generalized, indiscriminate intrahepaticocyte damage. Indirect hepatotoxins can be cytotoxic, producing steatosis or necrosis, or cholestatic producing jaundice (4,5).

Hepatic injury which depends on host idiosyncracy can also be divided into two types. The liver injury produced by some drugs after a fixed latent period (usually one to four weeks) is usually accompanied by systemic (fever, rash, eosinophilia) and histological (tissue eosinophilia or granulomas) features which suggest hypersensitivity to the drug as the cause. Often, the circumstances under which the injury occurs, and the response to a challenge dose, confirm drug allergy in these instances, and the inference is drawn that the drug or a metabolite has acted as a hapten (4,5,8,9).

The liver damage induced by other drugs, however, also in uniquely susceptible individuals, after a widely variable latent period and accompanied by ancillary features suggestive of hypersensitivity, may be deduced to be the result of some other mechanism, perhaps a metabolic aberration of the idiosyncratic patient, permitting the accumulation of hepatotoxic metabolites (4,5).

Knowledge of presumed mechanism and type of hepatic injury permits the classification of hepatotoxic agents shown in Table 2. While this classification may be subject to change as knowledge of mechanisms of injury increases, it has proved useful.

**Hepatic Injury Due to Intrinsic Toxicity of Drugs**

**Direct Hepatotoxins**

There are no known direct hepatotoxins that are used as therapeutic or diagnostic agents. CCl_{4}, formerly used as a vermifuge, has been largely abandoned, and tannic acid, which was at one time employed to treat burns and more recently in barium sulfate preparations to improve the quality of colonic radiographic studies, has been dropped from clinical use or employed in subtoxic concentrations for x-ray studies.

**Indirect Hepatotoxins**

Indirect hepatotoxins include a number of therapeutic agents (Table 2). Among the cytotoxic, indirect toxins are some antibiotics (e.g., tetracycline) and a large number of agents employed in the chemotherapy of neoplastic disease. Many of these agents produce hepatic steatosis by interfering with synthesis of appropriate apoprotein or with assembly of the lipoprotein complex required for the transport of lipid from the liver (5). Some drugs (e.g., urethane) that are categorized as cytotoxic indirect hepatotoxins produce necrosis by a mechanism that remains to be understood. Perhaps it is analogous to the necrogenic effect of bromobenzene which may be related to covalent binding to cytoplasmic proteins (10), although the means by which this leads to necrosis is obscure.

Tetracycline (and its congeners) is an antibiotic in clinical use which is illustrative of the indirect, cytotoxic hepatotoxins. High doses lead, in patients and experimental animals, to a diffuse vacuolization of hepatocytes that consists of tiny droplets of lipid and nonlipid material. It appears as a clinically important lesion only when high blood levels of tetracycline are produced by IV doses in excess of 1.5 g/day. The lesion seems particularly prone to occur if the recipient is in the last trimester of pregnancy or has renal disease. Smaller IV doses or oral administration usually produce no clinical evidence of hepatic disease, although minor degrees of steatosis can be observed in biopsy sections of the liver even after oral doses (5).

The mechanism for the steatosis has been demonstrated to be rapid inhibition by tetracycline of movement of lipid from the liver (5,11). Whether this is related to the known ability of these antibiotics to interfere with protein synthesis, perhaps by binding of tRNA or by interference with some other element of the complex system of synthesis or assembly of the lipoprotein necessary to transport the lipid from the liver, is unknown (5,11).

Ethanol also warrants classification as a drug which is an indirect hepatotoxin. It leads to fatty metamorphosis by a number of adverse effects on hepatocyte metabolism (12), but this is not within the scope of this paper.

**Cholestatic Indirect Hepatotoxins**

These toxins produce jaundice or impaired liver function by selective interference with hepatic mechanisms for excretion of substances.
into a canaliculus or uptake from the blood (5). A number of C-17 alkylated anabolic steroids are in this category. The effect of these agents is dose-related, but modified by the individual susceptibility of the recipient. Hepatic dysfunction is produced in most individuals, but jaundice in only a few. Impairment of bromosulphalein excretion occurs within a few days. Continued administration of the agent usually leads to a plateau or even to some decrease in the degree of abnormality of hepatic function. This would suggest that adjustment to and compensations for the adverse effects of the drug occur in most individuals, and that patients who develop jaundice after prolonged administration of one of these steroids are unable to make this adjustment, perhaps on a genetic basis (4).

Similar to this phenomenon is the high incidence of a relatively slight degree of hepatic dysfunction in women who take oral contraceptive steroids, which consist of C-17 alkylated estrogen and progesterone derivatives. Curiously, the oral contraceptive agents are particularly likely to produce jaundice in women who have had the benign, cholestatic jaundice of pregnancy, a syndrome with a probable genetic basis (5). Also probably related to this phenomenon is the impairment of liver function produced by estradiol and a number of other estrogenic agents (13).

The mechanism for the impaired function induced by these anabolic, progestational and estrogenic steroids is unknown. The available evidence suggests precise structural requirements, namely, an alkyl group at C-17. Testosterone, which lacks this type of substituent, does not lead to impaired function, while methyltestosterone, identical in structure except for the C-17 methyl substituent, does. A number of other agents with C-17 alkyl substituents also produce jaundice. This suggests the still unconfirmed hypothesis that these steroids might lead to impaired excretion of bile and its constituents by competitive interference with the transcanaliculat transport (4) or excretory (14) role of a bile acid or other metabolite.

A variant of the cholestatic type of indirect hepatotoxicity includes that caused by agents which produce unconjugated hyperbilirubinemia and interfere with the uptake of foreign dyes from sinusoidal blood. In this category are flavaspidic acid, gallbladder dyes, and rifampicin (5,9). Rifampicin also appears to interfere with clearance of bilirubin and foreign dyes by competitive inhibition of their biliary excretion (15). Novobiocin can also lead to unconjugated hyperbilirubinemia, especially in neonates, apparently by interfering with bilirubin conjugation (9).

**Hepatic Injury Due To Host Idiosyncrasy**

Many drugs produce hepatic injury, unpredictably, in a small proportion of recipients. The hepatic injury appears to be an expression of unique, individual susceptibility rather than of intrinsic toxicity of the offending agent (4,5,8,9). Some analyses have referred to these as hypersensitivity reactions, a designation that tacitly assumes or explicitly regards the mechanism to be that of drug allergy, and the two terms have been employed interchangeably in this context. Indeed some instances, described below, of drug induced injury probably are a manifestation of allergy. Others appear to represent a different mechanism, presumably an aberrant metabolic pathway for the drug in the susceptible patient. Accordingly, to avoid confusion, hepatic injury induced by a drug sporadically, unpredictably and in low incidence should be designated as an idiosyncratic response to the drug. The term hypersensitivity should be reserved for hepatic injury which appears to result from allergy to the drug (5).

**Hypersensitivity**

Allergy is presumed to be the mechanism when the hepatic injury is characterized by (a) a relatively fixed "sensitization" period of one to four weeks; (b) prompt recurrence of hepatic dysfunction or jaundice on readministration of small doses of the agent; (c) a high incidence of fever, rash and eosinophilia; (d) eosinophil-rich inflammatory infiltration, or granulomas in the liver; and (e) the coincidence of blood dyscrasias that also appears to depend on hypersensitivity for its pathogenesis (5). These features, however, provide only circumstantial evidence for drug hypersensitivity as the cause of hepatic disease (5). Efforts to demonstrate a role for humoral or cell-mediated immunity by the study of clinical cases have yielded variable results, and there are no experimental counterparts.

Indeed, no firm evidence for the role of hypersensitivity in drug induced hepatic injury has been available. The significance of the demonstration of antiliver antibodies in apparently drug-induced hepatic disease and of antimito-
chondrial antibodies in the serum of patients with several forms of apparently drug-induced injury, is uncertain (5). The studies of Paronetto and Popper (16) and those of Opolon et al. (17), suggest that in vitro transmigration of lymphocytes can be employed to demonstrate a relationship between an administered drug and hepatic injury in the recipient. While this technique has been useful for the study of generalized hypersensitivity reactions to drugs (17), a firm relationship to hepatic injury has not yet been shown.

The search for evidence of drug allergy as the cause of hepatic injury is hampered by the realization that the antigen responsible for the presumed allergic state might be an unknown metabolite of the drug rather than the administered molecule (18). Despite the lack of concrete evidence, drug allergy is probably responsible for many instances of hepatic disease. For example, sulfonamides, p-aminosalicylic acid, chlorpromazine, organic arsenicals, oxyphenisatin, methylidopa and halothane produce hepatic injury under circumstances which suggest that drug allergy plays an important role (5). Other drugs, however, produce hepatic injury in an equally small proportion of exposed individuals, but uncomplicated by clinical features that suggest drug allergy (4,5).

Even agents which appear to satisfy the criteria for hypersensitivity warrant closer scrutiny. While chlorpromazine, erythromycin estolate and triacetyloleandomycin produce clinically apparent hepatic injury in approximately 1% of recipients, the incidence of hepatic dysfunction has been observed to be much higher (40-50%) (4,5). These figures are too high to permit the assumption of hypersensitivity alone as the mechanism for the hepatic abnormality. Furthermore, some agents (e.g., penicillin) which produce overt generalized hypersensitivity, rarely produce hepatic injury (5). These observations have led to the hypothesis that some agents have a mildly adverse effect on the liver, which, when accompanied by hypersensitivity, may be expressed as a lowers liver disease (5,19). Support for this hypothesis has derived from studies utilizing suspensions of Chang liver cells maintained in tissue culture, suspensions of rat hepatocytes and the perfused rat liver (20-24). These studies have demonstrated a correlation between the adverse effects on these in vitro models of several phenothiazines (20-22) and several erythromycin derivatives (23,24), and the potential of these agents to cause hepatic injury in patients.

Metabolic Abnormality

A number of drugs produce hepatic injury in a small proportion of exposed individuals, under conditions that do not conform to the criteria for hypersensitivity as the mechanism (4,5,19). These reactions are characterized by a variable latent period rather than a fixed period of sensitization, no accompanying rash, fever, or eosinophilia, no eosinophilic or granulomatous inflammatory response in the liver, and failure to produce the hepatic injury with a single challenge dose of the drug. To produce the hepatic injury caused by these agents seems to require re-administration of the drug for a period of days or weeks. The possibility has already been cited that this form of hepatic injury results from a metabolic abnormality that permits very high levels of the drug or the accumulation of hepatotoxic metabolites. Evidence to support this view, however, remains to be developed.

The hepatic injury that results from host idiosyncrasy to drugs may be cytotoxic, cholestatic or mixed (4,5). The mechanism by which host idiosyncrasy induces cytotoxic or cholestatic jaundice is unknown. A look at the phenomenon of the curious form of hepatic injury that has been observed after halothane anesthesia (25), provides a basis for fruitful speculation (19). The incidence of halothane-induced jaundice is very low. Most observers consider it to be the result of allergy to the agent. This view is supported by the occurrence of fever and eosinophilia in more than 50% of patients with apparent halothane-induced jaundice, and by the observation that previous exposure to halothane appears to predispose to hepatic injury form the anesthetic (19). Not all patients with jaundice, however, have collateral evidence of allergy after halothane exposure. Furthermore, the nature of the hepatic lesion observed in many fatal cases, centrilobular necrosis (26), is much like that produced by CCl₄ (19). The lesion produced by CCl₄ appears to be caused mainly by a metabolite (the free radical, ·CCl₃) (27). The centrilobular localization of CCl₄ necrosis has been attributed to the relative concentration in the centrilobular area of drug-metabolizing enzyme systems (28). Accordingly, the centrilobular necrosis observed in fatal cases of halothane- and methoxyfluorane-induced jaundice, suggests that individuals whose metabolic aberration permits production or accumulation of hepatotoxic metabolites may develop, by a similar mechanism, the lesion which resembles that of CCl₄ (19). The metabolic aberration responsible
for the enhanced susceptibility might be genetic or acquired as the result of prior exposure to the agent or to other drugs and chemicals (19). Combined effects of generalized hypersensitivity and mild toxicity due to hepatotoxic metabolites might, in a manner similar to that proposed for other drugs, also be responsible for the hepatic injury of halothane (19).

This inference would suggest the hypothesis that the type of hepatic injury resulting from idiosyncratic metabolism of a drug depends on the nature of the hepatotoxic metabolite (19). If it injured, in a manner analogous to that of CCl₄, the membranes of intracytoplasmic organelles, it would produce lesions like those of the direct hepatotoxins. If the metabolite resembled the mediators of cytotoxic or cholestatic indirect hepatotoxins, the respective lesions might be expected. It may also be speculated that the form of hepatic injury produced as a manifestation of drug allergy might depend on tissue antibodies in the respectively injured cell type, or on localization to the respective cell type of tissue-damaging antigen antibody complexes or cyto-lytic factors from stimulated lymphocytes. Evidence for these speculations remains wanting.

Analysis of Hepatotoxic Reactions Induced by Drugs According to Clinical Circumstances of Exposure

Some of the many drugs which can produce hepatic injury are listed in Table 3, according to category of clinical use. Table 3 indicates the type of injury produced and the apparent mechanism of toxicity. For some drugs, there is sufficient information to describe the type of hepatic injury with some confidence. For the drugs designated as indirect toxins, there is reasonable experimental basis to support this mechanism of injury. For most drugs, the mechanism remains largely speculative and no distinction has been made in the Table between apparent hypersensitivity or metabolic abnormality as the basis for idiosyncrasy.

Despite the difficulties in assembling reliable data on drug-induced hepatic injury, a number of general relationships between the category of pharmacological effect and the apparent mechanism and form of hepatic injury can be derived. As mentioned earlier, the hepatic injury owing to all the tranquilizing drugs is usually hepatocanicular, and it appears, at least in part, to be induced by hypersensitivity, while almost all the antidepressants produce hepatocellular injury as a result of host idiosyncrasy, not necessarily of the drug allergy type. The hydrazine derivatives used in the treatment of tuberculosis produce hepatic injury, similar to that of the chemically related antidepressants (5). Diphenylhydantoin and other anticonvulsant drugs generally produce hepatocellular or mixed-hepatocellular injury apparently induced by hypersensitivity. The C-17 alkylated steroids usually produce canalicu-lar jaundice ("bland cholestasis") as indirect hepatotoxicity. The patterns of injury are less consistent for the oral antidiabetic drugs, the antithyroid drugs and sulfonamide derivatives.

These observations of the similarity of the hepatic injury produced by different members of a class of therapeutic agents pose an intriguing question. Is the mechanism for, and type of toxic effect on the liver related to the mechanism for the intended therapeutic effect on other organs?

Serum Enzyme Measurement in Experimental Hepatotoxicity

Serum enzymology and experimental hepatotoxicity have had an intimate relationship. Development of clinically or experimentally useful enzyme tests for the recognition of hepatic disease [e.g., glutamate-oxaloacetate transaminase (aspartate aminotransferase; GOT), ornithine carbamyl transferase (OCT), sorbitol dehydrogenase (SDH), arginase, guanase, isocitrate dehydrogenase (ICDH)] has depended on the study of the effects of experimental hepatotoxic states on serum levels of the enzyme. For this, known hepatotoxins, e.g. carbon tetrachloride, employed under standardized conditions, have been used.

Measurement of serum enzyme activities has provided a powerful tool for studies of hepatotoxicity. It has been employed in testing for toxicity of agents whose effects are unknown and in studying the circumstances and factors which influence the effects of known hepatotoxins. Study of factors that enhance (e.g., phenobarbital pre-treatment) or depress (e.g., inhibition of metabolism) CCl₄ toxicity has been critically aided by monitoring the extent of injury with serum enzyme assay. Moreover, demonstration of the promptness of injury is facilitated by serum enzyme measurement [GOT, glutamate pyruvate transaminase (alanine aminotransferase, GPT), ICD, OCT, SDH], as is identification of organelle injury, by measuring serum levels of enzymes.
Table 3. Mechanism of types of hepatic injury produced by drugs in various therapeutic categories.

| Type of agent                                      | Pattern of injury                                      |
|---------------------------------------------------|-------------------------------------------------------|
|                                                   | Hepatocellular or mixed hepatocellular | Hepatocanalicular or mixed hepatocanalicular | Canalicular |
| General anesthetics                               | Chloroform, Trichlorethylene, Halothane, Methoxyfluorane, Fluoroxene | Chlorpromazine and related phenothiazines, Ectylurea, Chloridiazepoxide, Diazepam, Imipramine |
| Neuro- and psychotropic agents                    |                                                       |                                                       |
| Tranquilizers                                     |                                                       |                                                       |
| Antidepressants                                   | Iproniazid and congeners Amityriptylene               |                                                       |
| Anticonvulsants                                   | Diphenylhydantoin Phenylacety lurea and congeners    |                                                       |
| Drugs employed in rheumatic and musculoskeletal disease and as analgesics | Cinchophen, Zozaxolamine, Ibufenac, Indomethacin, Phenylbutazone, Salicylates, Acetaminophen | Propoxyphene |
| Drugs used in endocrine disease or as hormonal substitutes | Propylthiouracil, Carbutamide, Metahexamide, Acetohexamide | Methimazole, Thiouracil, Chlorpropamide, Tolbutamide, C-17 alkylated anabolic steroids, Contraceptive steroids, Estradiol |
| Antimicrobial agent                               | Tetacycline and congeners Chloramphenicol, Triacetyloleandomycin, Penicillin, Griseofulvin, Paraminosaliclyc acid, Isoniazid, Ethionamide, Pyrazinamide, Rifampicin, Sulfonamides, Sulfoines | Erythromycin estolate, Novobiocin, Rifampicin, Organic arsenicals, Nitrofurantoin, Idoxuridine, Xenylamine |
| Agents used in cardiovascular disease             | Phenindione, Procainamide, Quindine, $\alpha$-Methylldopa, Nicotinic acid, Papaverine | Ajmaline, (?)*p*-Aminobenzylecaffeine hydrochloride |
| Antineoplastic chemotherapeutic agents            | Cause steatosis, Actinomycin D, 4-Aminopyrazolo pyrimidine, L-Asparaginase, Azacytidine, Azaauridine, Bleomycin, Cycloheximide | 4,4'-Diaminodiphenylamine, Busulfan, Azathioprine |
Table 3. Mechanism of types of hepatic injury produced by drugs in various therapeutic categories (Cont’d.).

| Type of agent | Hepatocellular or mixed hepatocellular | Hepatocanalicular or mixed hepatocanalicular | Canalicular |
|---------------|--------------------------------------|--------------------------------------|------------|
| **Antineoplastic chemotherapeutic agents (Cont’d.)** | Cause steatosis | Chromomycin | Mitomycin | N-Diazoacetylglycine hydrazide | Puromycin | Methotrexate (also causes cirrhosis) | Cause necrosis | Calvacin | Mithramycin | Urethane | Cyclophosphamide | Chlorambucil | 6-Mercaptopurine |
| **Miscellaneous agents** | Tannic acid | Carbamazepine | Carbamazepine | Carbamazepine | Trimethobenzamide | Tripelemamine | Oxyphenisatin | Phenazopyridine |

* Direct hepatotoxin.  
+ Possibly indirect hepatotoxin.  
Indirect hepatotoxin.  
All other agents apparently depend on host idiosyncrasy, either hypersensitivity or metabolic abnormality.

that arise in mitochondria [e.g., glutamate dehydrogenase (GDC), mitochondrial isoenzymes (GOT-II, MDH(m)), endoplasmic reticulum [e.g., liver monoesterase (LME), glucose-6-phosphatase (G-6-Pase)] and, conceivably, lysosomes.

Employment of serum enzymes as markers of hepatic injury requires awareness of the relative specificity of an enzyme test as a reflection of hepatic disease (Table 4) and knowledge of the mechanisms that can lead to altered enzyme levels in the serum (Table 5) and of the relationship between known hepatotoxic states and elevated enzyme levels.

Table 4. Groups of serum enzymes according to their levels in experimental or clinical hepatic disease.

| Group | Enzymes* | Obstructive jaundice and intrahepatic cholestasis | Acute necrosis | Chronic diseases | Diseases of other organs* |
|-------|----------|-----------------------------------------------|----------------|----------------|-------------------------|
| I A   | AL PH, S'N, LAP, GTP | Markedly increased | Increased | Increased | ± |
| I B   | GOT, MDH, LDH, ALD | Increased | Markedly increased | Increased | Increased |
| I C   | GPT, ICDH, GDH | Increased | Markedly increased | Increased | Increased |
| I D   | OCT, SDH, LDH, guanase, F-P-ALD, arginase | Increased | Markedly increased | Increased | ± |
| III   | CPK | Normal | Normal | Normal | Increased |
| IV    | CHE | Normal | Normal | Decreased | Decreased |

* AL PH = alkaline phosphatase; S'N = 5' nucleotidase; LAP = leucine aminopeptidase; GTP = glutamyl transpeptidase; LDH = isoenzyme of lactate dehydrogenase; CPK = creatinine phosphokinase; CHE = cholinesterase; MDK = maleate dehydrogenase; ALD = fructose diphosphate aldolase; GPT = glutamate pyruvate transaminase; ICPH = isocitrate transferase; SDH = sorbitol dehydrogenase; F-P-ALD = fructose monophosphate aldolase.

* I = insignificant or minimal change.
Table 5. Mechanisms for abnormal serum enzyme levels.

| Increased levels | Decreased levels |
|------------------|------------------|
| Increased release due to |
| Necrosis |
| Increased permeability without necrosis |
| Increased production and release |
| Decreased disposition |

REFERENCES

1. Boake, W. C., et al. Intrahepatic cholestatic jaundice in pregnancy. Am. J. Med. 63: 302 (1965).
2. Koff R. S., Profile of hyperbilirubinemia in three hospital populations. Clin. Res. 18: 660 (1970).
3. Trey, C., and Davidson, C. S. The management of fulminant hepatic failure. In: Progress in Liver Disease. H. Popper and F. Schaffner, Eds., Grune & Stratton, New York, 1970, Vol. 3, p. 282.
4. Zimmerman, H. J. Clinical and laboratory manifestations of hepatitis. Ann. N. Y. Acad. Sci. 104: 954 (1963).
5. Zimmerman, H. J. Drug-induced hepatic injury. In Hypersensitivity to drugs, M. Samter, Ed., Pergamon Press, Oxford, 1972, p. 299.
6. Dahl M. G. C., Gregory, M. M., and Scheuer, P. J. Liver damage due to methotrexate in patients with psoriasis. Brit. Med. J. 1: 625 (1971).
7. Reynolds, T. B., Peters, R. L., and Yamada, S. Chronic, active, and lupoid hepatitis caused by a laxative, oxphenisatin. N. Engl. J. Med. 285: 813 (1971).
8. Klatskin G. Toxic and drug induced hepatitis. In Diseases of the Liver, L. Schiff, Ed., 3rd ed., Lippincott, Philadelphia, 1969, p. 498.
9. Sherlock, S. Disease of the Liver, 4th ed., F. A. Davis, Philadelphia, 1968, p. 350.
10. Mitchell, J. R., Jollow, D. J., and Gillette, J. R. Relationship between metabolism of foreign compounds and liver injury. Israel J. Med. Sci. 10: 338 (1974).
11. Brenn, K., Schenker, S., and Heimberg, M. The effect of tetracycline on the hepatic secretion of triglyceride. Biochim. Biophys. Acta 70: 74 (1972).
12. Lieber, C. S., Rubin, E., and DeCarli, L. M. Effects of ethanol on lipid, uric acid, intermediary and drug metabolism, including the pathogenesis of the alcoholic fatty liver. In: The Biology of Alcoholism, B. Kissin and H. Begleiter, Eds., Plenum Press, New York, 1971, Vol. 1, p. 268.
13. Gallagher, T. F., Mueller, M. N., and Kappas, A. Estrogen pharmacology. IV. Studies on the structural basis for estrogen-induced impairment of liver function. Medicine (Baltimore) 45: 471 (1966).
14. Schaffner, F., and Raisfeld, U. H. Drugs and the liver: a review of metabolism and adverse reactions. Adv. Inter. Med. 15: 221 (1969).
15. Accocella, G., Nicolis, F. B., and Tenconi, L. T. The effect of an intravenous infusion of rifamycin SV on the excretion of bilirubin, bromsulphalein, and indocyanine green in man. Gastroenterology 49: 521 (1965).
16. Paronetto, F., and Popper, H. Lymphocyte stimulation induced by halothane in patients with hepatitis following exposure to halothane. N. Engl. J. Med. 283: 277 (1970).
17. Opolon, P., et al., Application du test de transformation lymphohistologique (TTL) au diagnostic de certaines hepatites medicamenteuses. Presse Med. 77: 2041 (1969).
18. Levine, B. B. Immunochemical mechanisms of drug allergy. Ann. Rev. Med. 17: 23 (1966).
19. Zimmerman, H. J. The spectrum of hepatotoxicity. Perspect. Biol. Med. 12: 135 (1968).
20. Dujovne, C. A., Levy, R., and Zimmerman, H. J. Hepatotoxicity of phenothiazines in-vitro as measured by loss of aminotransferases to surrounding media. Proc. Soc. Exptl. Biol. Med. 128: 561 (1968).
21. Zimmerman, H. J., and Kendler, J. Relationship between structure of phenothiazines and in-vitro cytotoxicity. Proc. Soc. Exptl. Biol. Med. 135: 201 (1970).
22. Kendler, J., et al. Effect of chlorpromazine on the function of the perfused isolated liver. Biochem. Pharmacol. 20: 2439 (1971).
23. Dujovne, G. A., et al. Experimental bases for the different hepatotoxicity of erythromycin preparations in man. J. Lab. Clin. Med. 79: 832 (1972).
24. Kendler, J., et al. Perfusion of the isolated rat liver with erythromycin estolate and other derivatives. Proc. Soc. Exptl. Biol. Med. 139: 1272 (1972).
25. Conn, H. O. Halothane-associated hepatitis. A disease of medical progress. Israel J. Med. Sci. 10: 403 (1974).
26. Peters, R. L., et al. Am. J. Med. 47: 748 (1969).
27. Becknagel R. O., et al. New data in support of the liperoxidation theory for carbon tetrachloride liver injury. Israel J. Med. Sci. 10: 300 (1974).
28. Slater, T. F. Neurogenic action of carbon tetrachloride in the rat: a speculative mechanism based on activation. Nature 209: 36 (1966).